Loading...

Kingworld Medicines Group Limited

1110.HKHKSE
Healthcare
Medical - Pharmaceuticals
HK$0.55
HK$-0.02(-3.51%)

Kingworld Medicines Group Limited 1110.HK Peers

See (1110.HK) competitors and their performances in Stock Market.

Peer Comparison Table: Medical - Pharmaceuticals Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
1110.HKHK$0.55-3.51%324.3M6.88HK$0.08+5.76%
6160.HKHK$147.80+0.27%210.6B-67.18-HK$2.20N/A
0241.HKHK$4.74-2.47%76.4B47.40HK$0.10N/A
3613.HKHK$8.67+0.58%7.3B14.45HK$0.60+4.04%
1345.HKHK$2.13-0.93%2.5B15.21HK$0.14+4.88%
3390.HKHK$0.37+0.00%330.8M37.00HK$0.01N/A
2211.HKHK$1.17+3.54%93.7M4.88HK$0.24N/A
0348.HKHK$0.07+0.00%53.9M-1.40-HK$0.05N/A
0574.HKHK$0.03-6.45%42.8M-2.90-HK$0.01N/A

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

1110.HK vs 6160.HK Comparison

1110.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 1110.HK stands at 324.3M. In comparison, 6160.HK has a market cap of 210.6B. Regarding current trading prices, 1110.HK is priced at HK$0.55, while 6160.HK trades at HK$147.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

1110.HK currently has a P/E ratio of 6.88, whereas 6160.HK's P/E ratio is -67.18. In terms of profitability, 1110.HK's ROE is +0.06%, compared to 6160.HK's ROE of -0.12%. Regarding short-term risk, 1110.HK is less volatile compared to 6160.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1110.HK.

Stock Price Comparison

Loading...

Frequently Asked Questions

;